secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001104659-26-013049
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing
--------------------------------------------------------------------------------

- Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.
- Cash and equivalents $31.6M at Dec 31, 2025, up from $18.5M; funded by public offering and ATM facility.
- R&D expenses $18.2M (up from $12.9M), G&A $9.4M (up from $6.9M); finance income $1.1M.
- NXP900 Phase 1b monotherapy enrolling; combination with osimertinib (EGFR-mutated NSCLC) enrolling; lorlatinib combo pending.
- CEO expects current cash to fund operations through multiple Phase 1b milestones into H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/0001104659-26-013049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/tm265090d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer